APA

Karlsson C., Norin S., Kimby E., Sander B., Porwit Macdonald A., Nilsson B., Johansson E., Mellstedt H., Lundin J. & Osterborg A. (20070920). Alemtuzumab as first-line therapy for B-cell chronic lymphocytic leukemia: long-term follow-up of clinical effects, infectious complications and risk of Richter transformation. : Leukemia.

Chicago

Karlsson C, Norin S, Kimby E, Sander B, Porwit Macdonald A, Nilsson B, Johansson E, Mellstedt H, Lundin J and Osterborg A. 20070920. Alemtuzumab as first-line therapy for B-cell chronic lymphocytic leukemia: long-term follow-up of clinical effects, infectious complications and risk of Richter transformation. : Leukemia.

Harvard

Karlsson C., Norin S., Kimby E., Sander B., Porwit Macdonald A., Nilsson B., Johansson E., Mellstedt H., Lundin J. and Osterborg A. (20070920). Alemtuzumab as first-line therapy for B-cell chronic lymphocytic leukemia: long-term follow-up of clinical effects, infectious complications and risk of Richter transformation. : Leukemia.

MLA

Karlsson C, Norin S, Kimby E, Sander B, Porwit Macdonald A, Nilsson B, Johansson E, Mellstedt H, Lundin J and Osterborg A. Alemtuzumab as first-line therapy for B-cell chronic lymphocytic leukemia: long-term follow-up of clinical effects, infectious complications and risk of Richter transformation. : Leukemia. 20070920.